Has David Kass received payments from drug or device companies?

Yes. Drug and device makers reported $90,286 in general payments to David Kass across 76 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Kass did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Kass come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Kass

Cardiovascular Disease · Baltimore, MDNPI 1588605877

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $81,235 of the $90,286 with a category attached, or 90.0%. 13 manufacturers reported payments, led by Amgen at 55.1% of the total. Reporting peaked in 2019 at $32,692 and has fallen 64.4% since, to $11,633 in 2025. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$90,286in general payments, 2019–2025

Across 76 payments — averaging $1187.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$50K
Janssen Research & Development, LLC$9K
Merck$8K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$7K
GSK$6K
AstraZeneca$3K
plus $7K from 7 others

$623,796in research payments, 2019–2025

Across 5 payments — averaging $124,759 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boehringer Ingelheim$404K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$215K
Eli Lilly$5K

What the payments were for

Consulting fees$81,23590%
Travel & lodging$7,7139%
Food & beverage$1,1731%
Education$1640%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	32	$49,781
Janssen Research & Development, LLC	2	$9,339
Merck	10	$8,315
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	3	$6,550
GSK	2	$5,850
AstraZeneca	2	$3,078
Sanofi-aventis U.S. LLC	5	$1,902
Boehringer Ingelheim International GmbH	1	$1,500
Boehringer Ingelheim	2	$1,181
Eli Lilly	12	$1,049
Modernatx, Inc.	1	$750
E.r. Squibb & Sons, L.L.C.	1	$500
Pfizer	3	$492

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,286 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland →

Other cardiovascular disease in Baltimore

Navin KapurBaltimore$1.5M
Michael BlahaBaltimore$609K
Sanjay RajagopalanBaltimore$521K
Erin MichosBaltimore$257K
Seth MartinBaltimore$166K
Erika FellerBaltimore$121K
Charles CummingsBaltimore$114K
John RickardBaltimore$109K
Christopher DefilippiBaltimore$101K
Hiroshi AshikagaBaltimore$90K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →